Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.

已完结 10 由 123 发布于 2026/8/10 15:47:04

DOI:10.1016/S2352-3026(18)30192-3
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S2352-3026(18)30192-3

Elsevier

Abstract：Background: Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands. We aimed to assess

应助信息

21小时前

同学羊小

686787d2949011f1879d34735aa3bc31.pdf 已采纳

21小时前

Book学术机器人

2026/8/10 15:47:04 未找到该文献，机器人已退出，请等待人工下载

2026/8/10 15:47:04 Book学术AI机器人收到请求，开始寻找文献

2026/8/10 15:47:04 已向机器人发送请求

21小时前

123 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierFrom black-box prediction to transparent process control: A physics-informed interpretable AI framework for total nitrogen management in WWTPs